[
    {"source":{"id":null,"name":"Business Wire"},"author":null,"title":"Aro Biotherapeutics Receives FDA Rare Pediatric Drug Designation for ABX1100 for the Treatment of Pompe Disease","description":"PHILADELPHIA--(BUSINESS WIRE)--Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Drug (RPD) designation for ABX…","url":"https://www.businesswire.com/news/home/20220915005101/en/Aro-Biotherapeutics-Receives-FDA-Rare-Pediatric-Drug-Designation-for-ABX1100-for-the-Treatment-of-Pompe-Disease","urlToImage":"https://mms.businesswire.com/media/20220915005101/en/695148/23/ARO_Full_Color_Logo_2018SEP05_F.jpg","publishedAt":"2022-09-15T13:06:59Z","content":"PHILADELPHIA--(BUSINESS WIRE)--Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced that the U.S. Food and Drug Administration… [+2207 chars]"},{"source":{"id":null,"name":"Business Wire"},"author":null,"title":"AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis","description":"CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted ra…","url":"https://www.businesswire.com/news/home/20220920005367/en/AVROBIO-Receives-Rare-Pediatric-Disease-Designation-from-U.S.-Food-and-Drug-Administration-FDA-for-First-Gene-Therapy-in-Development-for-Cystinosis","urlToImage":"https://mms.businesswire.com/media/20220920005367/en/774246/23/AVROBIO_LOGO.jpg","publishedAt":"2022-09-20T11:10:32Z","content":"CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the U.S.… [+8245 chars]"},{"source":{"id":null,"name":"Seeking Alpha"},"author":"SA Transcripts","title":"Sanofi (SNY) Presents at Citi's 17th Annual BioPharma Conference (Transcript)","description":"Sanofi (NASDAQ:NASDAQ:SNY) Citi’s 17th Annual BioPharma Conference September 7, 2022 2:40 PM ETCompany ParticipantsBill Sibold - EVP, Sanofi Genzyme; President Sanofi NA, Sanofi...","url":"https://seekingalpha.com/article/4539545-sanofi-sny-presents-citis-17th-annual-biopharma-conference-transcript","urlToImage":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","publishedAt":"2022-09-07T23:41:09Z","content":"Sanofi (NASDAQ:SNY) Citi’s 17th Annual BioPharma Conference September 7, 2022 2:40 PM ET\r\n Company Participants\r\n Bill Sibold - EVP, Sanofi Genzyme; President Sanofi NA, Sanofi SA\r\n Conference Call P… [+33055 chars]"},{"source":{"id":null,"name":"Business Wire"},"author":null,"title":"AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial","description":"CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the U.K. Medicines and Healthcare Products Regulatory Agen…","url":"https://www.businesswire.com/news/home/20220914005543/en/AVROBIO-Announces-Neuronopathic-Mucopolysaccharidosis-Type-II-nMPS-II-or-Hunter-Syndrome-Clinical-Trial-Application-CTA-Accepted-by-U.K.-Regulatory-Agency-to-Initiate-Pediatric-Phase-12-Gene-Therapy-Trial","urlToImage":"https://mms.businesswire.com/media/20220914005543/en/774246/23/AVROBIO_LOGO.jpg","publishedAt":"2022-09-14T11:39:58Z","content":"CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the U.K.… [+10519 chars]"},{"source":{"id":null,"name":"PRNewswire"},"author":null,"title":"Registration Now Open for 2023 MDA Clinical & Scientific Conference, to Showcase Cutting Edge Research Advancements and Clinical Achievements in Neuromuscular Disease","description":"The gathering of global leaders at MDA's annual conference will be presented both in-person in Dallas, TX, and virtually, March 19-22, 2023 NEW YORK, Sept. 12, 2022 /PRNewswire/ -- The Muscular Dystrophy Association (MDA) today announced that registration is …","url":"https://www.prnewswire.com/news-releases/registration-now-open-for-2023-mda-clinical--scientific-conference-to-showcase-cutting-edge-research-advancements-and-clinical-achievements-in-neuromuscular-disease-301621807.html","urlToImage":"https://mma.prnewswire.com/media/1895881/Muscular_Dystrophy_Association_Photo.jpg?p=facebook","publishedAt":"2022-09-12T13:00:00Z","content":"The gathering of global leaders at MDA's annual conference will be presented both in-person in Dallas, TX, and virtually, March 19-22, 2023\r\nNEW YORK, Sept. 12, 2022 /PRNewswire/ -- The Muscular Dyst… [+4620 chars]"}
]